Total Voting Rights
Creo Medical Group plc
("Creo" or the "Company")
Total Voting Rights
The Company's total issued share capital consists of 181,545,885 Ordinary Shares of 0.1 pence each ("Ordinary Shares") with one voting right per Ordinary Share. The Company does not hold any Ordinary Shares in Treasury.
Therefore, the total number of voting rights in the Company is 181,545,885 . This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Ends
Enquires:
|
Creo Medical Group plc |
|
|
Richard Rees (CFO) |
+44 (0)1291 606 005 |
|
|
|
|
Cenkos Securities plc |
+44 (0)20 7397 8900 |
|
Stephen Keys / Camilla Hume (NOMAD) |
|
|
Michael Johnson / Russell Kerr (Joint Broker) |
|
|
|
|
|
Numis Securities Limited (Joint Broker) |
+44 (0)20 7260 1000 |
|
Freddie Barnfield / James Black / Duncan Monteith |
|
|
|
|
|
Walbrook PR Ltd |
Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com |
|
Paul McManus / Sam Allen / Phillip Marriage |
Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 |
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information about Creo Medical please visit www.creomedical.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 51 minutes ago WH Smith
- 1 hour ago Staffline Group
- 1 hour ago Manchester & London Investment Trust
- 1 hour ago Associated British Foods
- 2 hours ago Centaur Media